MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-26-2026
Orgenesis P/B Ratio 2011-2026 | ORGS
Annual P/B Ratio Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.0691 | 0.631 | 1.98 | 2.74 | 14.7 | 2.17 | 3.95 | 3 | -2.77 | -8.73 | -15.9 | -126 | -10.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 | -126 | -10.4 |
P/B Ratio of other stocks in the Biotechnology industry
| Issuer | P/B Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
0.382 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
1.28 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
0.674 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
0.113 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
0.736 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-0.258 | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
2.26 | $ 2.56 | -6.41 % | $ 239 M |  Israel |
 |
I-Mab
IMAB
|
1.12 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
1.4 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
0.198 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
7.56 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.88 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
0.485 | $ 0.89 | 1.48 % | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
15.7 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
596 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
4.36 | $ 22.24 | -1.9 % | $ 3.69 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.13 | - | -1.52 % | $ 24.7 M | USA |
 |
Evogene Ltd.
EVGN
|
0.869 | $ 0.79 | -0.65 % | $ 27.9 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
4.76 | $ 6.15 | -8.21 % | $ 176 M | USA |
 |
Applied Molecular Transport
AMTI
|
0.364 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
0.492 | - | 1.93 % | $ 17.4 M | USA |
 |
Galapagos NV
GLPG
|
1.67 | $ 27.84 | -2.04 % | $ 2.69 B |  Belgium |
 |
Applied Therapeutics
APLT
|
-31.5 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
0.248 | - | -39.0 % | $ 4.57 M | USA |
 |
ImmuCell Corporation
ICCC
|
2.15 | $ 8.42 | 0.88 % | $ 76 M | USA |
 |
Avenue Therapeutics
ATXI
|
0.293 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
6.81 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
0.781 | - | 5.93 % | $ 314 M |  Canada |
 |
Innoviva
INVA
|
0.992 | $ 23.07 | -2.62 % | $ 1.55 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.994 | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
0.00262 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
5.67 | - | -13.39 % | $ 1.45 M | USA |
 |
Innate Pharma S.A.
IPHA
|
1.36 | $ 1.49 | 6.33 % | $ 235 M | France |
 |
Aridis Pharmaceuticals
ARDS
|
-0.17 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
0.625 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
5.29 | $ 100.23 | -1.8 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-0.815 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
1.64 | - | -4.8 % | $ 255 M | USA |
 |
Jaguar Health
JAGX
|
-0.0512 | $ 0.23 | -5.81 % | $ 536 K | USA |
 |
Inventiva S.A.
IVA
|
6.02 | $ 4.91 | -2.0 % | $ 138 M | France |
 |
Aquestive Therapeutics
AQST
|
-13.9 | $ 4.04 | -1.34 % | $ 432 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
18.2 | $ 22.36 | -3.99 % | $ 2.84 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
-308 | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Kamada Ltd.
KMDA
|
0.85 | $ 8.15 | - | $ 260 M | Israel |
 |
Autolus Therapeutics plc
AUTL
|
1.81 | $ 1.42 | -4.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
-0.511 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
2.07 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
0.594 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
32 | $ 2.95 | 1.2 % | $ 4.86 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
75.9 | - | 0.49 % | $ 251 B |  Cayman-islands |